UCB - Selling And Administration Expenses


UCB reported EUR1.47B in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Alcon AG USD 964M 82M Jun/2026
Almirall -29.5M 4.72M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
argenx SE USD 598M 181M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bayer EUR 4.02B 53M Sep/2026
Genmab DKK 205M 39M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
GRIFOLS EUR 326M 37M Sep/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.58B 11M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Orion EUR 98.9M 0 Sep/2026
Recordati EUR 189.59M 12M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
UCB EUR 1.47B 193M Dec/2025
Unibail Rodamco EUR 94.8M 4.8M Dec/2025